Ticagrelor Ticagrelor Ticagrelor (trade name Brilinta, Brilique, and Possia) is a platelet aggregation inhibitor produced by AstraZeneca. Ticagrelor is an antagonist of the P2Y receptor. The drug was approved for use in the European Union by the European Commission on December 3, 2010. The drug was approved by the US Food and Drug Administration on July 20, 2011. Ticagrelor is used for the prevention of thrombotic events (for example stroke or heart attack) in people with acute coronary syndrome or myocardial infarction with ST elevation. The drug is combined with acetylsalicylic acid unless the latter is contraindicated. There is no high
Technetium (99mTc) medronic acid Technetium (99mTc) medronic acid Technetium (Tc) medronic acid (MDP) is a pharmaceutical product used in nuclear medicine to localize bone metastases as well as other diseases that can alter the natural turn-over in the bone by bone scintigraphy. The drug is a complex of medronic acid, the simplest bisphosphonate, with technetium-99m (Tc), a radionuclide that emits gamma rays. The exact structure of the complex is not known. Tc-MDP must be prepared in a radiopharmacy. It is usually supplied as a "cold kit" to which radioactive Tc from a generator is added. Kit composition may vary between suppliers, but contents typically